Exagen Inc. updated earnings guidance for the full year 2024. For full year 2024 revenue, company is increasing guidance to at least $55 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.932 USD | -1.93% | -0.16% | -2.91% |
05-14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
05-13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.91% | 34.23M | |
+22.71% | 87.14B | |
-23.78% | 75.59B | |
+1.76% | 26.78B | |
+3.99% | 17.89B | |
-14.52% | 16.44B | |
+2.80% | 15.68B | |
+69.64% | 13.3B | |
+75.89% | 13.06B | |
+3.11% | 12.54B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Updates Earnings Guidance for the Full Year 2024